A Phase 2a Study to Evaluate the Dose-response, Safety, Tolerability, Efficacy, and Population Pharmacokinetics of Intravenous NTS-521 Infusions in the Early Recovery Treatment From Acute Ischemic Stroke
A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 140 participants.
Also called NCT07742098
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 140 participants
- Sponsor
- NeuroTrauma Sciences, LLC
- Registry
-
NCT07742098
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07742098. Randomized; quadruple masking; primary purpose treatment. Start 2026-10-31 (anticipated); primary completion 2028-12-15 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 2a Study to Evaluate the Dose-response, Safety, Tolerability, Efficacy, and Population Pharmacokinetics of Intravenous NTS-521 Infusions in the Early Recovery Treatment From Acute Ischemic Stroke
- Acronym
- ACT-IVATE
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- NTS-521
- Intervention (Other)
- Placebo Control
- Lead sponsor
- NeuroTrauma Sciences, LLC
Record details
- Record id
cardio:ct-nct07742098- Content hash
2b3da222cd2eac0e507cea1f4181a2ede254968fbe4f531bcecb5d46ef9dcec3